Coloplast A/S Announces Dividend of $0.04 (OTCMKTS:CLPBY)

Coloplast A/S (OTCMKTS:CLPBY) announced a dividend on Friday, May 16th, investing.com reports. Investors of record on Monday, May 19th will be given a dividend of 0.0389 per share on Thursday, May 22nd. This represents a yield of 2.02%. The ex-dividend date of this dividend is Friday, May 16th.

Coloplast A/S Price Performance

OTCMKTS:CLPBY opened at $9.60 on Friday. The company has a quick ratio of 0.66, a current ratio of 1.02 and a debt-to-equity ratio of 0.92. The company has a 50-day moving average of $10.39 and a 200 day moving average of $11.17. Coloplast A/S has a 1-year low of $9.43 and a 1-year high of $14.14.

Coloplast A/S (OTCMKTS:CLPBY) last announced its earnings results on Tuesday, May 6th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $7.02 billion. Coloplast A/S had a return on equity of 28.60% and a net margin of 17.81%. Research analysts anticipate that Coloplast A/S will post 0.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on CLPBY. Sanford C. Bernstein upgraded shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th. Barclays downgraded shares of Coloplast A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 7th. Finally, Royal Bank of Canada downgraded shares of Coloplast A/S from a “moderate buy” rating to a “hold” rating in a report on Friday, May 9th. Four analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.